Sanjeev Sockalingam, Scientific Director, framed the approval as a regulatory milestone that should "prompt governments, insurers, and employers to reconsider how obesity treatment is covered within these systems," noting that "fewer than 20 per cent of Canadians with private drug benefit plans have access to Health Canada-approved obesity treatment medications" [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]
GHK-Cu is not approved as a drug for any condition
Licochalcone A in combination with salicylic acid as fluid based and hydroxy-complex 10% cream for the treatment of mild acne: a multicenter prospective trial
R., Mahajan, V
Ceriello A, Novials A, Canivell S, La SL, Pujadas G, Esposito K, Testa R, Bucciarelli L, Rondinelli M, Genovese S